Torsdag 21 November | 15:30:42 Europe / Stockholm

Prenumeration

2024-11-12 17:51:00

Redeye provides an updated view on Genovis following a Q3 report that surpassed our estimates across the board. We have made slight adjustments to our model and largely reaffirm our fair value range, indicating a favorable risk/reward balance in the share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/